- Companies
- Prolific Machines
Prolific Machines Valuation, Funding & Investors
Prolific Machines is valued at $202M as of June 2024.
Last Prolific Machines valuation
$202M
Series B · Jun 2024
Last Prolific Machines funding round
$50M
Series B · Oct 2026
Cumulative funding Prolific Machines raised
$147M
across 3 funding rounds
Key investors in Prolific Machines
Breakthrough Energy Ventures
SOSV
Mayfield Fund
Ki Tua Fund
Mark Cuban
Breyer Capital
About Prolific Machines
Prolific Machines is a biotechnology company based in Emeryville, California, that uses optogenetics, light-responsive proteins that switch genes on and off inside living cells, to control protein expression in biomanufacturing. Founded in 2020, it combines optogenetics-enabled cell lines, add-on illumination hardware compatible with existing bioreactors, data-driven process optimisation and analytics, which lets producers separate cell growth from production and tune titres and critical quality attributes. The platform targets monoclonal antibodies, bispecific and multispecific antibodies, Fc fusions, cytokines and enzymes, with AAV viral vector production in development, and the company reports a titre of 21 g/L in a 15-day fed-batch antibody run on standard infrastructure. Prolific works with biotechs, pharmaceutical companies and contract development and manufacturing organisations, offering preclinical cell line and process development services, platform licensing and CDMO partnerships. In October 2026 it announced the initial closing of a USD 50 million Series B2 led by Atoms & Bits and Nant Capital, bringing its total funding above USD 100 million.
Founded
2020
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Services, Licensing
Valuation
$202M (Jun 2024)
Prolific Machines Valuation
Prolific Machines is currently valued at $202M, based on its Series B in June 2024.
The $55M round was led by Ki Tua Fund, with participation from Breakthrough Energy Ventures, Tet Ventures, Shorewind Capital, Conti Ventures, SOSV and 4 other investors.
Prolific Machines valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jun 2024 | Series B | $202M |
Prolific Machines Funding History
Prolific Machines has raised a total of $147M across 3 funding rounds.
Prolific Machines' first fundraising round was a $42M Series A in September 2022. The most recent completed round was a $50M Series B in October 2026.
Prolific Machines funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Oct 2026 | Series B | Atoms & Bits Capital (lead); NantCapital (lead); Ki Tua Fund; Breakthrough Energy Ventures; SOSV; Mayfield Fund | $50M | - | Prolific Machines announced on 14 October 2026 the initial closing of a USD 50 million Series B2 financing led by Atoms & Bits and Nant Capital. Existing investors Breakthrough Energy Ventures, Mayfield, SOSV and Fonterra's venture arm also participated, bringing total funding to more than USD 100 million. The company said it will use the capital to scale its optogenetics platform, expand programs with top-20 pharma companies and biotechs, grow its team and advance its technology across biologics, biosimilars and viral vector programs, with early work on tissue and organ fabrication. Prolific and NantWorks will also apply the platform to biologic programs within NantWorks' health and life sciences portfolio. Patrick Soon-Shiong, founder of NantWorks, and James Stewart, founder of Level One Fund and Atoms & Bits, joined the board. Prolific Machines is a biotechnology company advancing biologics development and manufacturing, based in Emeryville, California. It uses light-inducible cell lines, illumination systems and AI-driven process optimization to control protein expression in standard bioreactors, and works with biotech, pharma companies and contract development and manufacturing organizations. |
| Jun 2024 | Series B | Ki Tua Fund (lead); Breakthrough Energy Ventures; Tet Ventures; Shorewind Capital; Conti Ventures; SOSV; Darco Capital; Pledge Ventures; IQT; Mayfield Fund | $55M | $202M | Prolific Machines, based in Emeryville, California, develops a photomolecular biology platform that uses light to grow and control cells for biomanufacturing applications including cellular agriculture, nutritional and therapeutic proteins, tissue engineering, disease models, drug screening, cultivated meats, and pharmaceuticals. Founded in 2020 by CEO Deniz Kent, CTO Max Huisman, and CIO Declan Jones, the company introduces light-sensitive proteins to enable precise control over cellular processes, aiming to produce higher-quality biological products more efficiently and sustainably. On June 6, 2024, Prolific Machines announced the first close of a $55 million Series B financing round, including convertible notes, led by Ki Tua Fund, the corporate venture arm of Fonterra Co-operative Group. Participants included Breakthrough Energy Ventures, Mayfield, SOSV, Shorewind Capital, Darco Capital, Conti Ventures (or Continental Grains), In-Q-Tel (IQT), and others such as Pledge Ventures and Tet Ventures matching the query. This brought total funding to $86.5 million, following a prior $42 million round in 2021. The funding will support platform commercialization, customer acquisition, and partnerships, with commercial partners engaged but not yet announced. The company has proven control of cellular processes using light, transitioning from proof-of-concept to market delivery for products like whole cuts of cultivated meat, antibodies, and high-value ingredients. Investors highlighted the platform's potential for impact in human and environmental health across industries, with backing from strategic players like IQT for biosecurity and Fonterra for dairy-related innovations. |
| Sep 2022 | Series A | Breakthrough Energy Ventures (lead); Breyer Capital; David Adelman; David Rubenstein; Baruch Future Ventures; Mark Cuban; The Kraft Group; Michael Rubin; SALT Fund; Frederick Blackford; Jacob Poliskin; Purple Orange Ventures | $42M | - | Prolific Machines is a biotechnology company developing novel cell production technology to enable cost-competitive cultivated meat, likened to an 'assembly line for biology.' The company replaces expensive recombinant proteins needed for cell growth—reportedly up to 30,000 times costlier than gold per gram—with a method using control cells, aiming to slash manufacturing costs for meat alternatives like fish, poultry, and beef. Founded in 2020 by CEO Deniz Kent, physicist Max Huisman, and machine learning engineer Declan Jones, it graduated from SOSV's IndieBio accelerator, breaking records there. On September 14, 2022, Prolific Machines emerged from stealth, announcing a combined $42 million in massively oversubscribed Seed and Series A rounds, with the Series A led by Breakthrough Energy Ventures (BEV, founded by Bill Gates) and the Seed led by Arvind Gupta at Mayfield. Other investors included David Adelman, Mark Cuban, The Kraft Group, David Rubenstein, Michael Rubin, Breyer Capital, SALT Fund, Purple Orange Ventures, Frederick Blackford, Jacob Poliskin, and Baruch Future Ventures. A prior Pre-Seed was led by SOSV's IndieBio in late 2020. The Series A was raised about a year earlier but announced upon exiting stealth. Funds will support building a 25,000-square-foot headquarters in Emeryville, California, hiring, expanding assembly line programs, and developing a new production facility. The company plans to produce its own meat products and license technology to others, viewing it as a breakthrough for scalable biology to address climate change via sustainable food production. Prolific plans a $170 million Series B in Q1 2023. Investors like BEV and Mayfield praised the team's execution and potential to compete with conventional meat farming. |
Who has invested in Prolific Machines?
23 investors have backed Prolific Machines across its funding rounds, including Breakthrough Energy Ventures, SOSV, Mayfield Fund, Ki Tua Fund, Mark Cuban and Breyer Capital.
Lead investors include Atoms & Bits Capital, NantCapital, Ki Tua Fund and Breakthrough Energy Ventures.
Prolific Machines Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | Sep 2022 | ||
| 2 | Lead | Jun 2024 | ||
| 2 | Participant | Jun 2024 | ||
| 2 | Participant | Jun 2024 | ||
| 1 | Participant | Sep 2022 | ||
| 1 | Participant | Sep 2022 | ||
| 1 | Participant | Jun 2024 | ||
| 1 | Participant | Sep 2022 | ||
| 1 | Participant | Sep 2022 | ||
| 1 | Lead | Oct 2026 | ||
| 1 | Participant | Sep 2022 | ||
| 1 | Participant | Jun 2024 | ||
| 1 | Participant | Sep 2022 | ||
This data is available for Pro users. Sign up to see all 23 Prolific Machines investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialProlific Machines Competitors
Prolific Machines competitors include listed companies like ArcticZymes, Bloomage BioTechnology and Easy Holdings Co, and private ones like Verdezyne, BIOWEG and Cocoon Bioscience.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $12M | $1M | $119M | 6.4x | ||
| Private | - | - | $100M | - | ||
| Private | - | - | $95M | - | ||
| Private | - | - | $87M | - | ||
| Publicly listed | $631M | $104M | $2.4B | 4.1x | ||
| Publicly listed | $2.5B | $168M | $202M | - |
Prolific Machines Public Comps
Prolific Machines is still privately-owned, but its public comps include Easy Holdings Co, Korro Bio, Cabio Biotech (Wuhan) Co, Genomictree, Diaceutics, India Glycols, Pacific Edge, Jagsonpal Pharma, Bioventix and SDI Group.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $2.5B | $168M | 0.5x | - | 7.1x | - | |||
| $6M | ($112M) | 21.6x | 105.0x | (1.2x) | (1.6x) | |||
| $85M | $34M | 1.9x | - | 4.9x | - | |||
| $3M | ($7M) | 44.1x | 7.0x | (17.0x) | (15.0x) | |||
| $51M | $8M | 4.3x | 3.7x | 28.5x | - | |||
| $437M | $71M | 0.9x | 0.8x | 5.7x | 5.4x | |||
| $6M | ($20M) | 24.8x | 17.5x | (8.1x) | (9.4x) | |||
| $30M | $6M | 4.6x | - | 23.7x | - | |||
This data is available for Pro users. Sign up to see all Prolific Machines competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Prolific Machines
| When was Prolific Machines founded? | Prolific Machines was founded in 2020. |
| Where is Prolific Machines headquartered? | Prolific Machines is headquartered in Emeryville, United States. |
| Is Prolific Machines publicly listed? | No, Prolific Machines is a private, VC-backed company. |
| What is Prolific Machines' valuation? | Prolific Machines was last valued at $202M in its Series B in June 2024. |
| How much funding has Prolific Machines raised? | Prolific Machines has raised $147M across 3 funding rounds. |
| What was Prolific Machines' last funding round? | Prolific Machines' last funding round was a $50M Series B in October 2026, led by Atoms & Bits Capital and NantCapital. |
| Who are Prolific Machines' investors? | Prolific Machines' investors include Breakthrough Energy Ventures, Ki Tua Fund, SOSV, Mayfield Fund, Breyer Capital, David Adelman, Tet Ventures, David Rubenstein, Baruch Future Ventures, Atoms & Bits Capital and 13 others. |
| Which companies are comparable to Prolific Machines? | Companies comparable to Prolific Machines include ArcticZymes, Verdezyne, BIOWEG, Cocoon Bioscience, Bloomage BioTechnology and Easy Holdings Co. |
See companies similar to Prolific Machines
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




